The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC.
Yiran RongSujith RamachandranKaustuv BhattacharyaYi YangSally EarlYunhee ChangJohn P BentleyPublished in: Immunotherapy (2024)
Aim: This cohort study evaluated the association between immune checkpoint inhibitors (ICIs)-induced immune-related adverse events (irAEs) and mortality as well as ICI discontinuation among older adults with NSCLC. Methods: 2007-2019 Surveillance, Epidemiology and End Results-Medicare linked database was used and survival analysis with time-varying exposure of irAEs was applied to estimate the associations. Results & conclusion: A total of 8,175 individuals were included, with 46.8% of whom developed an irAE. Cox regression models showed the occurrence of any irAEs was associated with increased risk of mortality (HR: 1.73, 95% CI: 1.63-1.82) and treatment discontinuation (HR: 1.87, 95% CI: 1.78-1.97). Some variability was observed in the effect on the two outcomes depending on the type of irAE.
Keyphrases
- small cell lung cancer
- cardiovascular events
- risk factors
- advanced non small cell lung cancer
- public health
- risk assessment
- physical activity
- oxidative stress
- high glucose
- diabetic rats
- brain metastases
- cardiovascular disease
- emergency department
- healthcare
- adipose tissue
- endothelial cells
- combination therapy
- epidermal growth factor receptor
- health insurance
- weight loss
- glycemic control
- replacement therapy
- affordable care act
- data analysis